ADC oncology acquisition to address solid tumours
The acquisition will give Genmab worldwide rights to three clinical…
The acquisition will give Genmab worldwide rights to three clinical candidates including a potential best-in-class folate receptor alpha (FRα)-targeted ADC for ovarian cancer.